J Kobayashi1, T Maruyama, M Masuda, M Shinomiya. 1. Department of Internal Medicine, Chibaken Saiseikai Narashino Hospital, 1-1-1 Izumicho, Narashino, Chiba, 275-8580, Japan. koba231@attglobal.net
Abstract
BACKGROUND:Atorvastatin is a recently introduced statin that lowers LDL-cholesterol (LDL-C) and triglycerides more than some of the older statins. METHODS:Twenty-one Japanese hyperlipidemic subjects were treated with atorvastatin (10 mg/day) for 6 weeks. Plasma lipid concentrations and pre-heparin plasma LPL mass before and after oral administration were evaluated using an open crossover trial format. LPL mass in the pre-heparin plasma was measured by a sandwich enzyme immunoassay. RESULTS:Atorvastatin decreased plasma triglyceride (TG) concentration (-21%, p<0.05), as well as plasma total and LDL-cholesterol concentrations. LPL mass in the pre-heparin plasma did not change significantly by this treatment during this period. Both apolipoprotein (apo) B and E decreased considerably (-33%, p<0.001 for apo B; -29% p<0.001 for apo E), while apo A-I concentration did not change. Other clinical parameters such as body mass index, blood pressure, and fasting plasma glucose concentration of these subjects did not change during this treatment. CONCLUSIONS:Atorvastatin is effective in reducing plasma TG, which did not appear to be associated with an increased LPL mass.
RCT Entities:
BACKGROUND:Atorvastatin is a recently introduced statin that lowers LDL-cholesterol (LDL-C) and triglycerides more than some of the older statins. METHODS: Twenty-one Japanese hyperlipidemic subjects were treated with atorvastatin (10 mg/day) for 6 weeks. Plasma lipid concentrations and pre-heparin plasma LPL mass before and after oral administration were evaluated using an open crossover trial format. LPL mass in the pre-heparin plasma was measured by a sandwich enzyme immunoassay. RESULTS:Atorvastatin decreased plasma triglyceride (TG) concentration (-21%, p<0.05), as well as plasma total and LDL-cholesterol concentrations. LPL mass in the pre-heparin plasma did not change significantly by this treatment during this period. Both apolipoprotein (apo) B and E decreased considerably (-33%, p<0.001 for apo B; -29% p<0.001 for apo E), while apo A-I concentration did not change. Other clinical parameters such as body mass index, blood pressure, and fasting plasma glucose concentration of these subjects did not change during this treatment. CONCLUSIONS:Atorvastatin is effective in reducing plasma TG, which did not appear to be associated with an increased LPL mass.